Dyax Corp. and Merck KGaA Enter Into License Agreement for Discovery of Therapeutic Antibodies and Peptides

23-Aug-2005

Dyax Corp. announced that it has granted a non-exclusive license to its proprietary phage display libraries to Merck KGaA for the discovery and development of therapeutic antibodies and peptides. Under the terms of the agreement, Dyax receives an upfront technology license fee from Merck, as well as annual maintenance fees, clinical milestone payments and royalties on net sales of any products that may result from Merck's use of the Dyax libraries. In addition, Merck has an option for Dyax to perform funded research on its behalf. The agreement provides Merck with a license to Dyax's antibody and peptide phage display technology and patent rights, as well as sublicenses to relevant third-party antibody phage display patents that may be used with Dyax's technology.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance